
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>High-resolution Manometry in Treated Achalasia: Scoping Review and Novel Nomenclature</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>High-resolution Manometry in Treated Achalasia: Scoping Review and Novel Nomenclature</strong></summary>
            <div>
                <ul><li>This scoping review + expert recommendations provide guidance for HRM interpretation in treated achalasia.</li><li>It introduces novel descriptive terms for pathophysiology post-treatment.</li><li>Conventional Chicago Classification (CC) should NOT be used for treated achalasia description.</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>1. What is the recommended IRP cutoff for Medtronic systems to describe adequately treated achalasia (ATA)?</li><li>2. Which provocative maneuver is particularly relevant in assessing residual obstruction in treated achalasia?</li><li>3. What novel term is proposed for treated achalasia when features of EGJ obstruction or obstructive esophageal body spasms are present?</li><li>4. What is the significance of &#x27;delta-IRP&#x27; in evaluating treatment response in achalasia?</li><li>5. Beyond HRM, what other diagnostic tools are crucial for assessing clinical-manometric discordance and anatomical alterations in treated achalasia?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Background &amp; Problem Statement</strong></summary>
            <div>
                <ul><li>Chicago Classification (CC) is standard for primary motility disorder diagnosis, esp. achalasia.</li><li>CC lacks recommendations for HRM in treated achalasia (post-surgery/endoscopic interventions).</li><li>This gap leads to challenges in interpreting HRM findings post-treatment.</li></ul>
                
        <details>
            <summary><strong>HRM Evolution &amp; CC 4.0</strong></summary>
            <div>
                <ul><li>HRM revolutionized esophageal motility disorder diagnosis.</li><li>CC 4.0 improved specificity for diagnosis + achalasia subtyping.</li><li>HRM guides personalized management &amp; treatment for naïve achalasia.</li></ul>
                
        <details>
            <summary><strong>Advanced HRM Metrics</strong></summary>
            <div>
                <ul><li>Intra-bolus pressurization (IBP) + secondary position measurements → improved differential diagnosis.</li><li>Helps distinguish achalasia from esophagogastric junction outflow obstruction (EGJOO).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Clinical Need for Treated Achalasia Guidance</strong></summary>
            <div>
                <ul><li>Achalasia treatments (PD, LHM, POEM) are widespread.</li><li>Increasingly encountered in clinical practice.</li><li>Need for interpretation advice, optimal protocol, &amp; personalized management for treated patients.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Methodology</strong></summary>
            <div>
                <ul><li>Systematic scoping review of literature (Pubmed/MEDLINE, Embase, Web of Science) from inception to Dec 2024.</li><li>12 esophageal motility experts provided recommendations.</li><li>Proposed novel nomenclature &amp; management flowchart.</li></ul>
                
        <details>
            <summary><strong>Search Strategy &amp; Selection</strong></summary>
            <div>
                <ul><li>Adhered to PRISMA-ScR guidelines.</li><li>2 research questions guided keyword selection (PICO format).</li><li>Initial search yielded 9043 reports; 40 studies included after screening.</li></ul>
                
        <details>
            <summary><strong>Inclusion/Exclusion Criteria</strong></summary>
            <div>
                <ul><li>Included: Articles on HRM findings in treated primary achalasia.</li><li>Excluded: Pretreatment-only evaluations, studies w/o extractable HRM parameters, secondary/pseudo-achalasia.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Expert Consensus Process</strong></summary>
            <div>
                <ul><li>Statements/advice developed from systematic review + expert discussion.</li><li>Formal rating of evidence quality/recommendation strength NOT performed.</li><li>No IRB approval needed (published data review).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Novel Nomenclature &amp; Key Recommendations</strong></summary>
            <div>
                <ul><li>Conventional CC should NOT be used in treated achalasia description.</li><li>New terms proposed to describe pathophysiology post-treatment.</li><li>Guidance for HRM interpretation in treated achalasia.</li></ul>
                
        <details>
            <summary><strong>Adequately Treated Achalasia (ATA)</strong></summary>
            <div>
                <ul><li>Proposed term for treated achalasia w/o elevated IRP + no obstructive features in esophageal body.</li><li>IRP &lt;15 mmHg (Medtronic) / &lt;22 mmHg (Diversatek/Laborie).</li><li>Avoids confusion from &#x27;absent contractility&#x27; in CC.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Treated Achalasia with Outflow Obstruction (TAOO)</strong></summary>
            <div>
                <ul><li>Proposed term for treated achalasia w/ EGJ obstruction features OR obstructive esophageal body spasms.</li><li>IRP ≥15 mmHg (Medtronic) / ≥22 mmHg (Diversatek/Laborie).</li><li>Also includes RDC-IRP ≥10 mmHg, RDC-IBP (20 mmHg isobaric contour), repetitive PEP (30 mmHg), distal spasm, LES shortening.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Delta-IRP</strong></summary>
            <div>
                <ul><li>Difference between post-treatment &amp; pretreatment IRP.</li><li>Valuable tool to profile successfully treated achalasia.</li><li>Availability of pretreatment HRM measurement is advised.</li></ul>
                
        <details>
            <summary><strong>Predictive Value</strong></summary>
            <div>
                <ul><li>Significantly ↓ in clinical success (23 mmHg) vs failure (14 mmHg; P &lt; .001).</li><li>Cutoff of 16.5 mmHg predicted clinical success w/ ≥70% sensitivity &amp; specificity.</li><li>Objectively quantifies manometric improvement post-myotomy.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Residual Spastic Activity in Treated Type III Achalasia</strong></summary>
            <div>
                <ul><li>Term for spasms in esophageal body + clinical activity, ONLY if pretreatment diagnosis was spastic-type achalasia.</li><li>Requires retreatment, often w/ POEM (Supplementary Figure 4).</li><li>Indicates suboptimal clinical outcomes from PD or short myotomy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Peristaltic/Contractility Reappearance</strong></summary>
            <div>
                <ul><li>Presence of remnant peristalsis/contractility in esophageal body must be reported.</li><li>Term &#x27;reappearance&#x27; used as body contractility could be uncovered by LES-targeted treatments.</li><li>Correlates w/ radiographic success or treatment inefficacy.</li></ul>
                
        <details>
            <summary><strong>Patterns of Reappearance</strong></summary>
            <div>
                <ul><li>True peristaltic &#x27;recovery&#x27; is unlikely due to neuronal depletion.</li><li>Partial reappearance described in 28-60% of series.</li><li>Compartmentalized wave front (DCI &gt;450 mmHg) in type II achalasia → ↓ barium column height on TBE.</li><li>More common pattern in treated type II achalasia is IEM (mean DCI &lt;400 mmHg.cm.s).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendations Against</strong></summary>
            <div>
                <ul><li>Avoid &#x27;absent contractility&#x27; for treated achalasia (esp. type I) → fails to classify achalasia as primary motility disorder.</li><li>Avoid achalasia subtyping (types I, II, III) after treatment.</li><li>Pretreatment subtype features (e.g., PEP) are fundamental for guiding retreatment.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>HRM in Esophagogastric Junction (EGJ) Assessment</strong></summary>
            <div>
                <ul><li>IRP &amp; LESP significantly ↓ after successful achalasia treatment.</li><li>No major discordance between POEM, LHM, or PD in ↓ IRP/LESP.</li><li>Mean post-treatment IRP: 13 mmHg (vs 33 mmHg pretreatment).</li></ul>
                
        <details>
            <summary><strong>IRP Cutoffs &amp; Clinical Success</strong></summary>
            <div>
                <ul><li>IRP &lt;15 mmHg (Medtronic/Given) / &lt;22 mmHg (Diversatek/Laborie) / &lt;26 mmHg (Starlet) → successful treatment.</li><li>&lt;15 mmHg IRP (Medtronic/Given) effective for clinical responders (&lt;10% discordance).</li><li>IRP ≥15 mmHg (or 22 mmHg) → OR 2.1 for predicting symptom persistence.</li><li>Sensitivity &gt;87% in predicting clinical response after LES myotomy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Impact of Treatment Modality on EGJ Physiology</strong></summary>
            <div>
                <ul><li>PD results in lesser ↓ IRP &amp; LESP vs POEM/LHM.</li><li>PD correlates w/ clinical improvement, but higher median IRP in symptomatic persistence (15.5 mmHg) vs clinical success (9.0 mmHg).</li><li>Myotomy (LHM/POEM) generally reliable for IRP &lt;15/22 mmHg.</li></ul>
                
        <details>
            <summary><strong>Management of Elevated Post-treatment IRP</strong></summary>
            <div>
                <ul><li>Elevated post-treatment IRP can be managed conservatively w/ good outcomes if symptoms limited.</li><li>LES-directed retreatment can achieve efficient results in ≈60% of cases.</li><li>Age &amp; esophageal anatomy (sigmoid vs non-sigmoid) unlikely to affect EGJ relaxation post-treatment (esp. POEM).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Esophagogastric Junction-Contractile Integral (EGJ-CI)</strong></summary>
            <div>
                <ul><li>EGJ-CI is higher in achalasia patients vs controls.</li><li>Declines after LES-targeted treatment.</li><li>EGJ-CI &lt;30 mmHg associated w/ clinical &amp; radiographic success.</li><li>Possible role in post-POEM follow-up due to association w/ post-treatment reflux burden.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Provocative Maneuvers: Rapid Drink Challenge (RDC)</strong></summary>
            <div>
                <ul><li>RDC (continuous rapid swallowing of 200 cc water) is relevant for treated achalasia assessment.</li><li>Symptomatic treated patients more frequently show IBP &gt;20 mmHg, higher max IBP, higher IRP (&gt;10-12 mmHg), &amp; higher trans-EGJ gradient.</li><li>Negative predictive value of normal RDC-IRP (≤10 mmHg) was 94% (97% w/ normal trans-EGJ gradient).</li></ul>
                
        <details>
            <summary><strong>Correlation with Radiologic Obstruction</strong></summary>
            <div>
                <ul><li>RDC findings correlated w/ radiologic obstruction on Timed Barium Esophagogram (TBE) after multiple LES-targeted treatments.</li><li>Performing RDC as part of HRM protocol is valuable in treated achalasia.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>HRM Assessment of Esophageal Body</strong></summary>
            <div>
                <ul><li>CC is NOT applicable for distinguishing achalasia subtype after treatment.</li><li>Lack of concordance of EGJ metrics &amp; body contractility patterns pre- &amp; post-treatment.</li><li>Evaluation of body contractility provides valuable info on clinical &amp; radiologic outcomes.</li></ul>
                
        <details>
            <summary><strong>Treated Achalasia Subtypes &amp; Contractility</strong></summary>
            <div>
                <ul><li>Treated type I achalasia often shows absent contractility + low IRP (&lt;15 mmHg) if successful.</li><li>Type II/III achalasia often show PEPs/IBP w/ spastic (DL ≤4.5 sec) contractility + high pretreatment IRP.</li><li>May show remnant esophageal body contractility even after successful treatment.</li></ul>
                
        <details>
            <summary><strong>Persistent Obstruction Indicators</strong></summary>
            <div>
                <ul><li>Retained PEP or IBP w/ elevated pressure (&gt;20 mmHg) → suggests remnant obstruction.</li><li>Especially if associated w/ elevated IRP.</li><li>Progressive pressure build-up in distal esophagus over multiple swallows → reflects persistent outflow resistance @ EGJ.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Type III Achalasia Specifics</strong></summary>
            <div>
                <ul><li>Often characterized by higher pre- &amp; postoperative IRP.</li><li>Clinical success ↓ vs other subtypes, even w/ ↓ IRP post-myotomy.</li><li>PD &amp; LHM less effective in type III achalasia.</li></ul>
                
        <details>
            <summary><strong>Reasons for Reduced Efficacy</strong></summary>
            <div>
                <ul><li>PD is LES-limited treatment.</li><li>Standard myotomy only targets LES, may NOT ablate entire esophageal body spastic segment.</li><li>Suboptimal outcomes + distinctive manometric pattern (&#x27;residual spastic activity in treated type III achalasia&#x27;) → requires retreatment (POEM).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Tailored Management</strong></summary>
            <div>
                <ul><li>Management of type III achalasia is nuanced.</li><li>Should be tailored to individual patient after thorough phenotyping.</li><li>Radiographic &amp; manometric characteristics determine optimal myotomy length.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Repeated Treatment of Previously Treated Achalasia</strong></summary>
            <div>
                <ul><li>Less is known about HRM in retreated achalasia.</li><li>LESP &amp; IRP are ↓ in previously treated achalasia vs treatment-naïve patients, even if unsuccessful.</li><li>PD is most frequent treatment w/ symptom relapse → affects IRP values.</li></ul>
                
        <details>
            <summary><strong>Re-staging &amp; Assessment</strong></summary>
            <div>
                <ul><li>In patients w/ dysphagia, absent esophageal peristalsis, IRP ≤15 mmHg → treated achalasia w/ persisting/relapsing symptoms.</li><li>Important to restage disease using HRM to explore relapse mechanisms.</li><li>Supplement w/ TBE &amp; FLIP.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Efficacy of Retreatment Modalities</strong></summary>
            <div>
                <ul><li>Largest trial comparing PD &amp; POEM after unsuccessful LHM → higher Δ IRP &amp; LESP in POEM group.</li><li>Correlated well w/ clinical &amp; radiological endpoints.</li><li>HRM assessment after repeated treatments similar to post-initial treatment, w/ similar criteria.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Clinical-Manometric Discordance &amp; Adjunctive Tools</strong></summary>
            <div>
                <ul><li>HRM parameters do NOT always correlate w/ relapsing symptoms.</li><li>Discordance stems from anatomic alterations (end-stage achalasia, distal diverticulum, blown out myotomy (BOM)).</li><li>Radiological assessment (TBE) is fundamental to complement clinical, manometric, &amp; FLIP assessment.</li></ul>
                
        <details>
            <summary><strong>Functional Lumen Imaging Probe (FLIP)</strong></summary>
            <div>
                <ul><li>FLIP assessment is complementary (if not superior) to HRM.</li><li>Higher sensitivity in predicting clinical response to treatment (up to 95%).</li><li>Identifies subtle ↓ distensibility not evident on HRM/endoscopy, esp. in altered anatomy/post-treatment.</li><li>FLIP + HRM considerably improves EGJ physiology assessment post-LES treatments.</li></ul>
                
        <details>
            <summary><strong>EGJ Distensibility &amp; Prediction</strong></summary>
            <div>
                <ul><li>EGJ distensibility measured during FLIP correlated well w/ radiographic retention on TBE.</li><li>Sensitivity of 78% for EGJ-DI &lt;2.8 mm²/mmHg in patients w/ altered anatomy.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>High-Resolution Impedance Manometry (HRIM)</strong></summary>
            <div>
                <ul><li>HRIM provides further insights in identifying bolus retention.</li><li>Bolus flow time (BFT) from HRIM better predicted composite outcome (clinical + radiological success) w/ AUC 0.77 (vs 0.65 for EGJ-CI).</li><li>More complex HRIM metrics (clearance ratio, retention volume, 4D-HRIM) show potential.</li></ul>
                
        <details>
            <summary><strong>4D-HRIM Metrics</strong></summary>
            <div>
                <ul><li>Combination of pressure &amp; impedance calculations.</li><li>High correlation (0.7-0.8) &amp; inter-rater agreement (0.7-0.9) w/ standard HRM, FLIP, &amp; radiological results.</li><li>May improve HRIM accuracy, esp. in non-expert centers where FLIP is less available.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Timed Barium Esophagogram (TBE)</strong></summary>
            <div>
                <ul><li>Essential to assess esophageal emptying post-treatment.</li><li>Detects anatomic alterations (BOM, epiphrenic diverticula).</li><li>Forecasts treatment failure or sheds light on clinical-radiological discordance.</li><li>Remains a complementary tool; routinely considered in treated achalasia evaluation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>pH-Impedance Study &amp; Reflux Symptoms</strong></summary>
            <div>
                <ul><li>Reflux symptoms post-treatment may NOT always indicate true GERD.</li><li>Can result from stasis-related acidification of retained food.</li><li>If HRM/TBE are uninformative, perform EGD &amp; 24-hour pH-impedance study.</li><li>Complemented by FLIP to assess disguised EGJ distensibility alteration.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Management Flowchart for Treated Achalasia</strong></summary>
            <div>
                <ul><li>Clinical assessment should precede HRM after achalasia treatment.</li><li>If symptoms persist (dysphagia/reflux), perform complete manometric assessment.</li><li>Integrate HRM data w/ distensibility assessment (FLIP) &amp; TBE for comprehensive evaluation.</li></ul>
                
        <details>
            <summary><strong>Initial Steps</strong></summary>
            <div>
                <ul><li>Always consider TBE or barium contrast X-ray.</li><li>Evaluate EGJ morpho-physiology, esophageal body contractility, &amp; provocative maneuvers.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Identifying TAOO</strong></summary>
            <div>
                <ul><li>Elevated IRP (&lt;15/22 mmHg), high LESP, delta-IRP &lt;16.5 mmHg.</li><li>High EGJ-CI.</li><li>RDC: IBPs @ 20 mmHg, IBP max pressure &gt;30 mmHg, IRP &gt;10-12 mmHg, ↑trans-EGJ gradient.</li><li>Presence of residual spasm (DL&lt;4.5s) or PEP (30 mmHg) or IBP (&gt;20 mmHg).</li><li>If confirmed obstruction → retreatment.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Identifying ATA</strong></summary>
            <div>
                <ul><li>Absence of TAOO features.</li><li>If FLIP available, use as first choice.</li><li>Consider altered anatomy (BOM) if present.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Symptom-Specific Management</strong></summary>
            <div>
                <ul><li>If dysphagia prevalent: FLIP, TBE, ↓BFT @ HiRM (if available).</li><li>If reflux symptoms prevalent: EGD &amp; 24-h pH-impedance study to confirm acidic stasis.</li><li>Retreatment for &#x27;residual spastic activity in treated type III achalasia&#x27; → POEM of remnant spastic segment.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Conservative Management</strong></summary>
            <div>
                <ul><li>If only slightly elevated IRP w/o other clear obstruction signs → initial conservative management.</li><li>Should NOT prompt immediate LES-targeted retreatment.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Areas Warranting Further Research</strong></summary>
            <div>
                <ul><li>Lack of adequate patient-reported questionnaires specifically for treated achalasia w/ persisting symptoms.</li><li>Need for studies focusing on HRIM metrics in treated achalasia.</li><li>Development of novel, easy-to-use, reproducible HRM provocative metrics.</li></ul>
                
        <details>
            <summary><strong>HRIM Metrics</strong></summary>
            <div>
                <ul><li>Clearance ratio &amp; retention volume (already developed in naïve patients).</li><li>4D HRIM metrics (already developed in naïve patients).</li><li>Particularly relevant as HRIM may be more available than FLIP in non-expert centers.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Provocative Maneuvers</strong></summary>
            <div>
                <ul><li>Solid meal testing (w/ consensus on meal type/consistency/quantity).</li><li>Correlation of HRM outcomes of provocative maneuvers w/ radiology &amp; FLIP results.</li><li>Prediction of treatment outcome in patients w/ recurrent symptoms.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Symptom Assessment</strong></summary>
            <div>
                <ul><li>Development of validated patient-reported outcomes for treated achalasia.</li><li>Quality of life questionnaires focusing on dietary &amp; nutritional status post-treatment.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Reproducibility of HRM Data</strong></summary>
            <div>
                <ul><li>Evaluating reproducibility of HRM metrics in different measurements for treated achalasia.</li><li>Focus on provocative maneuvers &amp; concordance between primary/secondary position for EGJ metrics &amp; obstructive features.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
